Morningstar

Morningstar, Inc.

Equity Bottom-Up

No-moat Conmed reported first-quarter results that largely met our expectations, and we don’t foresee many changes to our model that will push our $60 fair value estimate significantly in either direction. Segment revenue and non-GAAP profits were consistent with our view, although GAAP profitability and cash flow suffered from higher interest expense and additional costs associated with the ongoing integration of Buffalo Filter. Organic revenue growth clocked in at 6.3%, toward the high end of…

United States

CONMED Corporation provides orthopedic products, specializing in arthroscopy and powered surgical instruments.  The Company develops, manufactures, and supplies surgical instruments and systems used in a range of surgical procedures.  CONMED's products include arthroscopic surgery devices and powered surgical instruments, electrosurgery systems, and ECG electrodes for heart monitoring.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00